P2.11A.05 The Impact of Tumor Molecular Features and Smoking History on Survival with Chemo-Immunotherapy in EGFR-Mutant NSCLC von Bodor, J.N., Zhou, Y., Cheung, M., Borghaei, H., Clapper, M.L., Treat, J.

Volltext

P2.07-04 Genomic Subtypes of EGFR-Mutant NSCLC and Real-World Progression-Free Survival (rwPFS) with Immunotherapy (IO) von Belani, N., Walzer, E., Deng, M., Handorf, E., Borghaei, H., Treat, J., Clapper, M., Bodor, J.N.

Volltext

Neighbourhood fruit and vegetable availability and consumption: the role of small food stores in an urban environment von Bodor, J Nicholas, Rose, Donald, Farley, Thomas A, Swalm, Christopher, Scott, Susanne K

Volltext

P2.12-07 Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression von Treat, J., Abdulla, N., Bank, B., Zuniga, R., Konduri, K., Gabrail, N., Ewesuedo, R., Bhatia, K., Bodor, J.N., Goto, Y.

Volltext

OA13.04 Profile of Reactive Estrogen Species in Women with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) von Bodor, J.N., Krzizike, D.D., Vanderveer, L., Eidbo, S., Zawislak, C.L., Ross, E.A., Andrews, A.J., Edelman, M.J., Treat, J., Clapper, M.L.

Volltext

P1.01-109 Phase II Trial of Pemetrexed/Carboplatin/Bevacizumab +/- Atezolizumab in NSCLC Patients That Are EGFR Mutated or Never Smoked von Bodor, J.N., Patel, J., Ross, E., Litwin, S., Treat, J.

Volltext

OA09.05 Lung Cancer as a Second Primary Malignancy Among Women with Breast Cancer: The Role of Hormone Replacement and Smoking von Bodor, J.N., Fisher, S., Treat, J., Clapper, M.

Volltext

A20 Estrogen Metabolism in Patients with EGFR-Mutated and ALK-Mutated Non-Small Cell Lung Cancer (NSCLC) von Bodor, J.N., Treat, J., Krzizike, D.D., Zawislak, C.L., Vanderveer, L., Yulis, M., Chau, A., Ross, E.A., Andrews, A.J., Clapper, M.L.

Volltext